September 19, 2014 9:15 AM ET

Pharmaceuticals

Company Overview of Bellicum Pharmaceuticals, Inc.

Company Overview

Bellicum Pharmaceuticals, Inc. operates as a biotherapeutics company that develops novel therapies for the treatment of cancer and other diseases. It offers AP1903, a lipid permeable and synthetic organic compound used in conjunction with a chemical induction of dimerization (CID) therapy; BPX-101, an autologous vaccine for the treatment of patients with metastatic castrate resistant prostate cancer and other cancers; and CaspaCIDe DLI (donor lymphocyte infusions), a self destruct switch used in the areas of stem cell therapy and hematopoietic stem cell transplantation. The company was founded in 2004 and is based in Houston, Texas.

6400 Fannin Street

Suite 2300

Houston, TX 77046

United States

Founded in 2004

Phone:

713-341-6472

Fax:

713-798-4950

Key Executives for Bellicum Pharmaceuticals, Inc.

President
Co-Founder and Chief Scientific Officer
Compensation as of Fiscal Year 2014.

Bellicum Pharmaceuticals, Inc. Key Developments

Bellicum Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 09:00 AM

Bellicum Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 09:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Thomas J. Farrell, Co-Founder, Chief Executive Officer and Director.

Bellicum Pharmaceuticals, Inc. Announces First Clinical Study of a Chimeric Antigen Receptor (CAR) T Cell Therapy

Bellicum Pharmaceuticals, Inc. announced that the first clinical study is underway of a Chimeric Antigen Receptor (CAR) T Cell therapy that incorporates a safety switch to enable rapid elimination of the administered T cells if they threaten the life or health of the patient. Researchers from the National Cancer Institute (NCI) have begun treating pediatric patients with osteosarcoma and other non-neuroblastoma. GD2-expressing solid tumors with a third generation CAR T cell therapy that incorporates Bellicum's unique CaspaCIDe(R) safety switch technology. Bellicum's CaspaCIDe technology consists of an inducible Caspase-9-based cell safety switch, and the small molecule activator, AP1903. CaspaCIDe is engineered into immunotherapy cells, in this case GD2-targeted third generation CAR T cells, before they are introduced to the patient. In the event of a serious or life threatening toxicity caused by the administered T cells, AP1903 is infused to trigger rapid destruction and elimination of the CaspaCIDe-enabled cells.

Bellicum Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 09:30 AM

Bellicum Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 09:30 AM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Similar Private Companies By Industry

Company Name Region
Natural Biosciences, Inc. United States
Aeropharm Technology LLC United States
Formula Pharmaceuticals, Inc. United States
Health & Beyond Nutra Company Inc. United States
BioRexis Pharmaceuticals Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 22, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bellicum Pharmaceuticals, Inc., please visit www.bellicum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.